TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05693675

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Postoperative placebo
Description: Participants will receive intraoperative methadone intravenously 0.2mg/kg followed by oral placebo postoperatively according to the following scheme: Opioid naïve patients and patients taking opioids preoperatively will receive placebo tablets twice daily on day 1 and day 2 and once daily day 3, 4 and 5. Patients taking preoperative opioids will be able to return to their baseline opioids immediately after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue Analgesia
Description: PACU analgesia for both groups will be the usual care regime of fentanyl or hydromorphone bolus as prescribed by the physician anesthesiologist doing the case. All patients receive IV intravenous patient-controlled analgesia and rescue opioids which is usual care for postoperative pain.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rescue Analgesia
Description: PACU analgesia for both groups will be the usual care regime of fentanyl or hydromorphone bolus as prescribed by the physician anesthesiologist doing the case. All patients receive IV intravenous patient-controlled analgesia and rescue opioids which is usual care for postoperative pain.
Study: NCT05891587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide pen injector

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution
Study: NCT05328258

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride solution 0.9%
Description: One injection compensating for 3 months' effect OR one injection compensating for 1 month' effect to maintain the study blind.
Study: NCT05969548

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active 3600-pulse continuous Theta Burst Stimulation
Description: Each patient will receive two 1800-pulse cTBS stimulations per day, parted by a 50-minute rest period (a total of 3600 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham 1200-pulse continuous Theta Burst Stimulation
Description: Each patient will receive two sham 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham 2400-pulse continuous Theta Burst Stimulation
Description: Each patient will receive two sham 1200-pulse cTBS stimulations per day, parted by a 30-minute rest period (a total of 2400 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
Study: NCT06162182

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: electrical impedance device,
Description: The electrical resistance of the residual dentine underneath each measurement point was determined between an electrode and the crown pulp (Prepometer, Hager \& Werken, Duisburg, Germany). Assigning the electrical resistance of the dentin. high values are considered to represent more residual dentine than low values.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Reference test: Digital Radiographic examination
Description: A digital periapical radiograph using paralleling technique was taken
Study: NCT05252468

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TaffiX™
Description: Personal nasal powder spray.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TaffiX™
Description: Personal nasal powder spray.
Study: NCT05033327

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Nutrition and Exercise app
Description: Personalized, home-based, interactive therapy app
Study: NCT05794841

Intervention type: DIAGNOSTIC_TEST
Intervention: Tongue coating sample collection and multi-omics analysis
Description: Tongue coating sample collection and multi-omics analysis for building a diagnostic model

Intervention type: DIAGNOSTIC_TEST
Intervention: Tongue coating sample collection and multi-omics analysis
Description: Tongue coating sample collection and multi-omics analysis for building a diagnostic model
Study: NCT05596331

Intervention type: OTHER
Group type: OTHER
Intervention: eye-tracker
Description: Eye-tracker recordings of eye movements, gaze direction and pupillary reactivity
Study: NCT06366568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluoride toothpaste containing 1450 ppm of MFP in a PCC base and eugenol gum product
Description: PARTICIPANTS WILL USE A EUGENOL BASED product PRIOR TO TOOTHBRUSHING

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fluoride toothpaste containing 1450 ppm of MFP in a PCC base
Description: toothbrushing 2x a day for 2 minutes each time
Study: NCT05999136

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulses diet
Description: Subjects in the PulD group will be assigned a personalized diet prepared based on their own eating habits as established by 7-day food diary recalls. Energy values of habitual diets will be kept unchanged during the PulD intervention. The diet will be characterized by isocaloric and isoprotein substitutions, replacing habitual servings of red meat or processed meat with servings of pulses.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant proteins diet
Description: Subjects in the PPD group will be assigned a personalized diet prepared based on their own eating habits as established by 7-day food diary recalls. Energy values of habitual diets will be kept unchanged during the PPD intervention. The diet will be characterized by isocaloric and isoprotein substitutions, replacing habitual servings of red meat or processed meat with a mixture of pulses and plant-based meat substitutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Habitual diet
Description: Control subjects will not change their habitual diet during intervention. All subjects will be requested not to change physical activity levels during the 8 week intervention period.
Study: NCT05969548

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham 3600-pulse continuous Theta Burst Stimulation
Description: Each patient will receive two sham 1800-pulse cTBS stimulations per day, parted by a 50-minute rest period (a total of 3600 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
Study: NCT05596331

Intervention type: OTHER
Group type: OTHER
Intervention: eye-tracker
Description: Eye-tracker recordings of eye movements, gaze direction and pupillary reactivity

Intervention type: OTHER
Group type: OTHER
Intervention: eye-tracker
Description: Eye-tracker recordings of eye movements, gaze direction and pupillary reactivity

Intervention type: OTHER
Group type: OTHER
Intervention: eye-tracker
Description: Eye-tracker recordings of eye movements, gaze direction and pupillary reactivity
Study: NCT04909333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Day1: After a standardized night meal (Maizena 40g plus dessert) at 22 p.m. on the day before, patients receive Exenatide study medication according to the randomization list (injection done slowly over 2 min.). Regular clinical examination of vegetative and neurological state will be done as well as continuous blood sugar measurements and blood withdrawals will be performed.~Day2:~The procedure is equal to study day 1. Instead of Exenatide, a 10ml 0.9% saline solution will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Day1: After a standardized night meal (Maizena 40g plus dessert) at 22 p.m. on the day before, patients receive Exenatide study medication according to the randomization list (injection done slowly over 2 min.). Regular clinical examination of vegetative and neurological state will be done as well as continuous blood sugar measurements and blood withdrawals will be performed.~Day2:~The procedure is equal to study day 1. Instead of Exenatide, a 10ml 0.9% saline solution will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Day1: After a standardized night meal (Maizena 40g plus dessert) at 22 p.m. on the day before, patients receive Exenatide study medication according to the randomization list (injection done slowly over 2 min.). Regular clinical examination of vegetative and neurological state will be done as well as continuous blood sugar measurements and blood withdrawals will be performed.~Day2:~The procedure is equal to study day 1. Instead of Exenatide, a 10ml 0.9% saline solution will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% saline solution
Description: Day1: After a standardized night meal (Maizena 40g plus dessert) at 22 p.m. on the day before, patients receive 0.9% saline solution according to the randomization list (injection done slowly over 2 min.). Regular clinical examination of vegetative and neurological state will be done as well as continuous blood sugar measurements and blood withdrawals will be performed.~Day2:~The procedure is equal to study day 1. Instead of 0.9% saline solution, Exenatide will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% saline solution
Description: Day1: After a standardized night meal (Maizena 40g plus dessert) at 22 p.m. on the day before, patients receive 0.9% saline solution according to the randomization list (injection done slowly over 2 min.). Regular clinical examination of vegetative and neurological state will be done as well as continuous blood sugar measurements and blood withdrawals will be performed.~Day2:~The procedure is equal to study day 1. Instead of 0.9% saline solution, Exenatide will be administered intravenously.
Study: NCT06275568

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Fresh Connect cardholder engagement
Description: Fresh Connect, a Food as Medicine product of the non-profit organization About Fresh, Inc., consists of a pre paid, programmable debit card, a cloud-based cardholder success platform, and an analytic engine designed to illuminate the healthcare value of improved food access and nutritional security.~This arm receives:~* About Fresh Food Rx debit card ($100 per month from enrollment until 2 months post-partum)~* Texts for all cardholders per month (1-2 outbound texts)~* Welcome call from About Fresh cardholder engagement team~* 1 text - notification that Fresh Connect funds have been reloaded~* As-needed program updates (e.g. new retailers), inactivity outreach~* Additional texts that would be ad hocs: texts with food experiences (cooking videos), produce how-tos, and fun engagement; and satisfaction surveys - e.g. feedback on the Fresh Connect program, feedback on retailers, satisfaction with cardholder success, etc.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care Fresh Connect cardholder engagement
Description: Fresh Connect, a Food as Medicine product of the non-profit organization About Fresh, Inc., consists of a pre paid, programmable debit card, a cloud-based cardholder success platform, and an analytic engine designed to illuminate the healthcare value of improved food access and nutritional security.~This arm receives:~* About Fresh Food Rx debit card ($100 per month from enrollment until 2 months post-partum)~* Texts for all cardholders per month (1-2 outbound texts)~* Welcome call from About Fresh cardholder engagement team~* 1 text - notification that Fresh Connect funds have been reloaded~* As-needed program updates (e.g. new retailers), inactivity outreach~* Additional texts that would be ad hocs: texts with food experiences (cooking videos), produce how-tos, and fun engagement; and satisfaction surveys - e.g. feedback on the Fresh Connect program, feedback on retailers, satisfaction with cardholder success, etc.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced engagement communication
Description: Enhanced engagement involves additional outbound texts per month and additional ad hoc bi-monthly or quarterly texts, as well as tailored reminder text to use funds before the end of the month.
Study: NCT06346496

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Douyin Xinqing AI dialog bot
Description: Douyin Xinqing is an AI dialog bot. Users can start chatting with the Douyin companion bot by clicking on the Direct Message on the homepage of their accounts on Douyin app.~After a user sends any message to the Douyin companion bot, it first asks the user about his or her mood and guides him or her to start chatting around his or her emotions. According to the situation described by the user, the companion bot expresses empathy, asks questions to guide the user to talk, and provides suggestions at the appropriate time. Users can also record their emotions every day and look back regularly to observe changes in their inner feelings. In addition, the Douyin companion bot can also identify crisis situations such as suicide and severe mental illness and, if necessary, guide users to call the hotline to obtain professional psychological assistance.

Intervention type: OTHER
Group type: OTHER
Intervention: Douyin Xinqing AI dialog bot for delayed intervention
Description: Only the users in the waiting group had the task of waiting for the first four weeks, and they completed the three questionnaires at exactly the same point in time as those in the intervention group. Only after the first four weeks of intervention did the waiting group begin to receive the 28-day conversational intervention, and no additional questionnaires were interspersed in between.
Study: NCT06234657

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telerehabilitation for stroke patient
Description: The subjects of the study were intervened by telerehabilitation through video instructions and online group training via Online meeting software. The content of the intervention program included upper limb exercises, transfer, and ambulation functions. This training program was designed based on the clinical practice guidelines for post-stroke physiotherapy management from the United States Department of Veterans Affairs and the guidelines for the diagnosis, and treatment of rehabilitation stroke patients of the Vietnam Ministry of Health. The training results of the subjects will be evaluated by the Barthel Index
Study: NCT06040554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elastic Band Resistance Exercises
Description: 8 Warm-Up Exercises followed by 10 Elastic Band Exercises followed by 8 Post-Workout Exercises.
Study: NCT05576740

Intervention type: PROCEDURE
Intervention: Determination of hormone level concentrations
Description: Determination of concentration of 17β-oestradiol (pg/mL), progesterone (ng/mL), LH (mUI/mL), FSH (mUI/mL), prolactin (ng/mL), total testosterone (ng/mL), free testosterone (pmol/L) sex hormone binding globulin (SHBG) (nmol/L), cortisol (μg/dL), T3 (ng/dL), T4 (mcg/dL), TSH (mcU/mL), basal insulin (mcUI/mL) during the early follicular phase, late follicular phase, and mid-luteal phase.

Intervention type: PROCEDURE
Intervention: Determination of hormone level concentrations
Description: Determination of concentration of 17β-oestradiol (pg/mL), progesterone (ng/mL), LH (mUI/mL), FSH (mUI/mL), prolactin (ng/mL), total testosterone (ng/mL), free testosterone (pmol/L) sex hormone binding globulin (SHBG) (nmol/L), cortisol (μg/dL), T3 (ng/dL), T4 (mcg/dL), TSH (mcU/mL), basal insulin (mcUI/mL) during the early follicular phase, late follicular phase, and mid-luteal phase.

Intervention type: PROCEDURE
Intervention: Determination of hormone level concentrations
Description: Determination of concentration of 17β-oestradiol (pg/mL), progesterone (ng/mL), LH (mUI/mL), FSH (mUI/mL), prolactin (ng/mL), total testosterone (ng/mL), free testosterone (pmol/L) sex hormone binding globulin (SHBG) (nmol/L), cortisol (μg/dL), T3 (ng/dL), T4 (mcg/dL), TSH (mcU/mL), basal insulin (mcUI/mL) during the early follicular phase, late follicular phase, and mid-luteal phase.

Intervention type: PROCEDURE
Intervention: Jump height determination
Description: by Chronojump contact mat, determine five types of jump in centimeters: Squat jump without additional weight, Squat jump with 50% of body weight, Countermovement jump, Abalakov jump, and Drop jump, during the early follicular phase, late follicular phase, and mid-luteal phase.
Study: NCT06303648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylone
Description: Oral dose of methylone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylone
Description: Oral dose of methylone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylone
Description: Oral dose of methylone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylone
Description: Oral dose of methylone
Study: NCT05456568

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LymphAssistTM Professional
Description: An intermittent pneumatic compression (IPC) device that mimics manual lymphatic drainage. Participants use the device daily for 12 weeks alongside their usual and standard lymphoedema care
Study: NCT04982926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS2940
Description: Study participants with solid tumors and EGFR or HER2 aberrations will receive TAS2940 tablets daily at increasing doses until MTD is reached.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS2940
Description: Study subjects with select solid tumors characterized by EGFR or HER2 aberrations will receive TAS2940 at the dose identified during Dose Escalation phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS2940
Description: Study subjects with select solid tumors characterized by EGFR or HER2 aberrations will receive TAS2940 at the dose identified during Dose Escalation phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS2940
Description: Study subjects with select solid tumors characterized by EGFR or HER2 aberrations will receive TAS2940 at the dose identified during Dose Escalation phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS2940
Description: Study subjects with select solid tumors characterized by EGFR or HER2 aberrations will receive TAS2940 at the dose identified during Dose Escalation phase.
Study: NCT06075329

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contemplative Practice
Description: Contemplative practice included Maitribodh Sambodh Dhyaan (MSD), which was designed to increase feeling of love and connection by including most of components of different contemplative practices such as breath watch, mantra or vibrational sound chant, focused meditation, and visualization followed by loving-kindness or a gratitude exercise at the end.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Contemplative Practice
Description: Contemplative practice included Maitribodh Sambodh Dhyaan (MSD), which was designed to increase feeling of love and connection by including most of components of different contemplative practices such as breath watch, mantra or vibrational sound chant, focused meditation, and visualization followed by loving-kindness or a gratitude exercise at the end.
Study: NCT06425939

Intervention type: OTHER
Group type: OTHER
Intervention: Force plate assessment
Description: On Day 1, Day 45 and Day 90: 3x drop jumps, 2 min rest, 3x counter movement jumps, 2 min rest, 3x dynamic push-ups

Intervention type: DEVICE
Group type: OTHER
Intervention: Whoop wrist band
Description: Whoop wrist worn activity tracker (not a medical device) collects continuous data via smartphone app. This is a marketed device. This is not a device study.
Study: NCT05346965

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Musical training
Description: The musical training intervention comprised songs, rhythm and visual creativity to encourage the children to experience music-making as fun.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Musical training
Description: The musical training intervention comprised songs, rhythm and visual creativity to encourage the children to experience music-making as fun.
Study: NCT05146713

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Propolis nanoparticles extract solution
Description: 20 mg/ml propolis nanoparticles in the form of solution prepared from honeybee from various plants.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium hypochlorite
Description: 2.5% sodium hypochlorite (household bleaching agent)
Study: NCT04929002

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05550818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Ultra Processed Food Diet
Description: Participants will be provided and consume a diet emphasizing UPF (81% energy). Diets will be eucaloric (50% carbohydrate, 35% fat,15% protein) matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, and overall diet quality, for 2 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Ultra Processed Food Diet
Description: Participants will be provided and consume a diet containing no UPF (0% energy). Diets will be eucaloric (50% carbohydrate, 35% fat,15% protein) matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, and overall diet quality, for 2 weeks.
Study: NCT04935359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIS793
Description: Concentrate for solution infusion (Liquid in Vial)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIS793
Description: Concentrate for solution infusion (Liquid in Vial)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Per locally approved formulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nab-paclitaxel
Description: Per locally approved formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Per locally approved formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Per locally approved formulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Per locally approved formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Per locally approved formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dextrose 5% in water (D5W) solution for infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dextrose 5% in water (D5W) solution for infusion
Study: NCT06558799

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-200T
Description: The NovoTTF-200T is a portable, battery operated system intended for continuous home use, which delivers TTFields at a frequency of 150kHz to the subject by means of insulated transducer arrays. TTFields exert electric forces intended to disrupt cancer cell division and induce immunogenic cell death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is an immune checkpoint inhibitor that helps the immune system recognize and attack cancer cells.